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Introduction: Xeroderma pigmentosum is a rare autosomal recessive disease that causes changes in skin
pigmentation, precancerous lesions and neurological abnormalities. It is a defect in the nucleotide excision repair
mechanism. It has been reported that volatile anesthetics has a possible genotoxic side effect and deranged
nucleotide excision repair in cells obtained from a patient with xeroderma pigmentosum.
We report an unusual case of postoperative neurological aggravation in a patient with xeroderma pigmentosum
anesthetized with sevoflurane.
Case presentation: A 24-year-old African woman, who has had xeroderma pigmentosum since childhood, was
admitted to our hospital for a femoral neck fracture. A preoperative physical examination revealed that she had a
resting tremor with ataxia. She had cutaneous lesions such as keratosis and hyperpigmentation on her face and
both hands. There was no major alteration of cognitive function, muscular strength was maintained and her
osteotendinous reflexes were preserved. Surgical fixation was performed under general anesthesia after the failure
of spinal anesthesia. All parameters were stable during surgery. When she woke up four hours later, the patient
presented with confusion and psychomotor agitation, sharpened reflexes and the Babinski reflex was present. Her
postoperative test results and a magnetic resonance imaging scan were unremarkable. It was suggested that
sevoflurane had had a probable deleterious effect on the neurological status of this patient.
Conclusion: The anesthetizing of a patient with xeroderma pigmentosum is associated with a risk of worsening
neurological disorders. At present, there are no clear recommendations to avoid the use of volatile agents in the
anesthetic management of patients with xeroderma pigmentosum. More clinical and experimental research is
needed to confirm the sensitivity of patients with xeroderma pigmentosum to sevoflurane and other halogenated
anesthetics.
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Xeroderma pigmentosum (XP) is a rare autosomal reces-
sive disease, which is characterized by hypersensitivity of
the skin to ultraviolet (UV) radiation and progressive
neurological complications. It is caused by a defect in the
nucleotide excision repair mechanism [1]. Estimated inci-
dences vary from 1 in 20,000 in Japan to 1 in 250,000 in
the USA, and approximately 2.3 per 1 million live births* Correspondence: mustaphabens_15rea@hotmail.com
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reproduction in any medium, provided the orin Western Europe. Anecdotally, the incidence in North
Africa and the Middle East is substantially higher [2].
Little information exists on the optimal anesthetic
management of these patients [3-6]. It has been
reported that volatile anesthetics have a genotoxic side
effect in the cells of patients with XP and may worsen
the symptoms [5,7]. However, up to now, there are no
human data for this effect [8]. This report aimed at de-
scribing a postoperative neurological complication after
general anesthesia in a patient with XP submitted totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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probability of sevoflurane as the factor of deterioration.
Case presentation
A 24-year-old African woman, who had had XP since
childhood, was admitted to our hospital for a femoral
neck fracture after a fall on the stairs. Surgical fixation
was indicated. A preoperative evaluation could not
determine the genetic type of her XP. She had minor
cutaneous forms on her face and on her hands, and had
no history of tumor surgery. A neurological examination
showed a minor decline in intelligence quotient (IQ),
and an end tremor of the extremities associated with
ataxic gait. She was calm, cooperative and oriented in
time and space, with preserved muscle strength and
deep tendon reflexes with no anomalies. A preoperative
magnetic resonance imaging (MRI) scan did not show
any sign of brain abnormalities. Her cardiovascular and
pulmonary evaluation and biological test results were
normal. The patient was premedicated with oral
hydroxizine (50mg the day before and 50mg the morn-
ing of surgery). In the operating room, we initiated
standard monitoring including pulse oximetry (SpO2),
precordial cardioscopy, and noninvasive blood pressure
(NIBP). A 16G peripheral venous catheter was secured
and 1g cefazolin was administered. The patient was
placed in a sitting position for the spinal anesthesia, and
an injection of hyperbaric bupivacaine (12.5mg) and
fentanyl (25μg) was given using a 25G Tuohy needle
after checking the flow of cerebrospinal fluid. However,
the motor and sensory blocks were insufficient. The pa-
tient’s Bromage score was 4 and her reaction to pinprick
was significant. We converted to a general anesthesia
induced by propofol 150mg, fentanyl 250μg, and
cisatracurium 8mg and maintained by 2% sevoflurane
with a 50% oxygen 50% air mixture. The procedure
lasted 80 minutes without incident. The patient’s NIBP
reading was between 136 and 92 as maxima, 81 and
56mm Hg as minima, her heart rate was 85 to 105 -
beats/minute and her SpO2 was between 98 and 100%.
Postoperative analgesia was assured by paracetamol (1g),
nefopam (20mg) and parecoxib (40mg). In the postoper-
ative recovery room, the patient remained intubated and
ventilated. Her unexplained nonawakening after about
one hour induced us to monitor her postoperative
residual curarization and to administer neostigmine. Her
motor response was satisfactory. However, she did not
wake up nor return to spontaneous ventilation after two
hours, which induced us to perform a biological assess-
ment (sodium, urea, glucose) that showed no abnormal-
ities. After three hours, we noticed signs of awakening
and spontaneous breathing. Her tidal volume was satis-
factory. The patient became agitated, with abnormal
movements that persisted despite the extubation,optimization of analgesia and a psychological reassur-
ance. On examination, signs of pyramidal irritation
appeared, such as sharpened reflexes, and the Babinski
reflex was present, which necessitated transferring the
patient to the MRI room for a scan; the images did not
show any lesions that could explain these symptoms.
Her agitation did reduce but other neurological disor-
ders persisted for more than three postoperative days,
with the appearance of memory disorders like false rec-
ognition and confusion in time and space. They were
attributed to a neurological worsening of XP. Postoper-
ative follow-up was recommended by neurologists.
After three months, she is still presenting with confu-
sion and cognitive decline, with memory disorders,
ataxia and spasticity.
Discussion
XP is a rare autosomal recessive disease, which is char-
acterized by hypersensitivity of the skin to ultraviolet
(UV) radiation and progressive neurological complica-
tions. It is mainly characterized by dermatological mani-
festations such as atrophy, keratosis, telangiectasis,
hyperpigmentation and neoplasias in areas exposed to
sunlight. The ophthalmologic symptoms are photopho-
bia, corneal lesions, bilateral cataracts and a higher risk
for benign and malignant eye tumors. There are eight
genetic types of XP [9]; seven different genes involved in
classical XP (XPA to XPG) and one gene for XP variant.
Only patients with XPC, XPE and XP variant do not
have neurological disorders, while the others show major
and progressive neurological abnormalities. In this
report, the genetic type of XP was not known, but it was
probably one of those associated with neurodegenerative
symptoms. Neurological abnormalities are found in 18%
of XP patients [9]. The most common are mental retard-
ation, spasticity, ataxia, microcephaly and peripheral
neuropathy. Before the surgery, our patient had a minor
decline of IQ, tremor of the extremities and ataxia. After
surgery she appeared to develop irreversible cognitive de-
cline, confusion, agitation and a pyramidal syndrome.
Bone fragility in XP patients is probably due to a vitamin
D deficiency related to patients’ protection from sunlight.
Little information exists on the optimal anesthetic
management of patients with XP. For this type of sur-
gery, a spinal anesthesia was chosen initially to prevent
any neurological repercussions that could be caused by
general anesthesia. After the failure of this technique,
the available alternative was a general anesthesia induced
by propofol, fentanyl, and cisatracurium and maintained
by sevoflurane. There was no event that could explain
the irreversible postoperative neurological degradation
in our case. There was no hemodynamic instability, no
transient hypoxia, and no electrolytic disorder was
found. In the recovery room, residual curarization was
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tion. A postoperative MRI scan did not show any cere-
bral lesions. Neurological disorders occurred in our
patient, which could be attributed to the worsening of
her XP symptoms by peri-operative factors including
anesthetic agents.
The contribution of general anesthesia/anesthetics to
postoperative cognitive decline (POCD) as a clinical
entity has not been established, because patients under
general anesthesia do not have an increased rate of
POCD compared with patients under regional anesthesia
[8]. But, a recent pilot study indicates that patients
under isoflurane anesthesia may have a higher rate of
POCD than patients under desflurane anesthesia after
lower extremity or abdominal surgery [10]. In this case,
surgical factors appeared to be controlled, and neurotox-
icity of the medication is probably the most likely
etiology.
Beyond that, it is not possible to separate the inhala-
tional anesthetic effects from those of other anesthetic
agents. Some evidence suggests that these unwanted
effects vary according to each hypnotic’s specific phar-
macodynamic and pharmacokinetic characteristics and
its interaction with the individual patient [11]. Propofol
reduces cerebral blood flow and cerebral O2 metabolism
to a similar extent, has favorable pharmacokinetics and a
high-quality recovery profile despite prolonged infusion
[12,13]. Fentanyl is a half-life opioid analgesic. Its
primary actions of therapeutic value are analgesia and
sedation with a favorable side-effect profile and it may
increase the patient’s tolerance for pain [14,15].
Data on volatile anesthetics-induced neurotoxicity in
animal studies are accumulating rapidly [8]. However,
there are, as yet, no human data for this effect. There
has been no prospective randomized clinical trial to
evaluate volatile anesthetics-induced neuroprotection or
neurotoxicity [8]. For XP patients, Masuda et al. [5]
recommend avoiding inhalation anesthetics and using
total intravenous anesthesia (TIVA), based on a report
by Reitz and Lanz [7]. These authors showed deoxyribo-
nucleic acid (DNA) strand breaks and irreversible DNA
exchange in the lymphocytes of two patients with XP
after in vitro exposure to halothane and speculated
about a possible genotoxic side effect of this drug.
Karabiyik et al. [16] also showed transitory DNA damage
by sevoflurane in human lymphocytes similar to
isoflurane studied in vivo.
Associated with anesthetics-induced cell injury and
death in neonatal animals, volatile anesthetics have also
been shown to impair the cognitive functions of these
animals [8]. There is, however, a lack of evidence for the
causal relationship between the cell injury/death in the
brain and the cognitive impairment in the animals after
anesthetic exposure, both in the relationship betweenthe genetic disorder in XP neuronal cells and the mech-
anism of sevoflurane-induced neurotoxicity.
On the other hand, volatile anesthetics have been used
in clinical practice for nearly 160 years and are still the
most commonly used anesthetics worldwide. Sevoflurane
is often chosen for such patients based on its favorable
properties for pediatric anesthesia, its ease of use, its mal-
leability, and its clinical safety reported during its use even
at high concentrations in inhalational anesthesia using a
mask [4]. In our institution, sevoflurane has been used
since 2006 with approximately 30 operations per day. Its
safety is demonstrated but our experience with XP
patients is still poor.
In clinical practice, among XP patients submitted to
general anesthesia, Miyazaki et al. [6] reported a case of
transient worsening of the neurological symptoms after
anesthesia with volatile agents in previous surgery,
whereas the intraoperative management and the postop-
erative course were uneventful with TIVA. Because the
neurological deterioration in our patient appears to be
probably related to the deleterious effects of anesthetics
and sevoflurane is probably the most likely etiology be-
cause of its potential genotoxicity, we would suggest
more experimental and clinical studies to affirm and
explain a probable sensitivity of the neurodegenerative
form of XP to volatile anesthetics. In the meantime, a
preoperative neurological assessment is especially neces-
sary in patients with the neurodegenerative genetic type
XP, and using the TIVA option is preferable.
Conclusion
The anesthesia of a patient with XP is associated with a
risk of worsening neurological disorders. Because of their
genotoxicity, based on experimental studies and case re-
ports, the use of volatile anesthetics may have an adverse
effect that has not yet been confirmed. At present, there
are no clear recommendations to avoid volatile agents in
the anesthetic management of patients with XP. More
clinical and experimental research is needed to confirm
the sensitivity of XP patients to sevoflurane and other ha-
logenated anesthetics.
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